Downregulation of the Na(+)-creatine cotransporter in failing human myocardium and in experimental heart failure.
about
Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathyCreatine kinase in ischemic and inflammatory disordersOral creatine supplementation facilitates the rehabilitation of disuse atrophy and alters the expression of muscle myogenic factors in humansXanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts.Creatine transporter protein content, localization, and gene expression in rat skeletal muscle.ATP flux through creatine kinase in the normal, stressed, and failing human heart.Gene expression and phenotypic characterization of mouse heart after chronic constant or intermittent hypoxia.Energy metabolism in heart failure.No effect of creatine supplementation on oxidative stress and cardiovascular parameters in spontaneously hypertensive rats.Augmentation of Creatine in the Heart.Regression of pathological cardiac hypertrophy: signaling pathways and therapeutic targets.On the hypothesis that the failing heart is energy starved: lessons learned from the metabolism of ATP and creatine.Mitochondrial centrality in heart failure.Energy metabolism in heart failure and remodelling.Experimentally observed phenomena on cardiac energetics in heart failure emerge from simulations of cardiac metabolism.New aspects of impaired mitochondrial function in heart failure.Normal cardiac function in mice with supraphysiological cardiac creatine levelsPotential of metabolic agents as adjunct therapies in heart failure.Expert consensus document: Mitochondrial function as a therapeutic target in heart failureCreatine as an antioxidant.Cardiac metabolism in hypertrophy and heart failure: implications for therapy.Role of the phosphocreatine system on energetic homeostasis in skeletal and cardiac muscles.Potential of creatine or phosphocreatine supplementation in cerebrovascular disease and in ischemic heart disease.Exposing cardiomyocytes to subclinical concentrations of doxorubicin rapidly reduces their creatine transport.Metabolic remodelling in hypertrophied and failing myocardium: a review.Effects of N-linked glycosylation on the creatine transporter.Cyclosporin A inhibits creatine uptake by altering surface expression of the creatine transporter.Creatine--a dispensable metabolite?Creatine transporter and mitochondrial creatine kinase protein content in myopathies.New creatine transporter assay and identification of distinct creatine transporter isoforms in muscle.Mitochondrial creatine kinase is critically necessary for normal myocardial high-energy phosphate metabolism.Novel mitochondrial creatine transport activity. Implications for intracellular creatine compartments and bioenergetics.Thyroid hormone regulation of cardiac bioenergetics: role of intracellular creatine.Human, rat and chicken small intestinal Na+ - Cl- -creatine transporter: functional, molecular characterization and localization.Creatine transporter activity and content in the rat heart supplemented by and depleted of creatine.Muscle creatine uptake and creatine transporter expression in response to creatine supplementation and depletion.Creatine supplementation reduces doxorubicin-induced cardiomyocellular injury.PIKfyve in the SGK1 mediated regulation of the creatine transporter SLC6A8.Cardiac protection with phosphocreatine: a meta-analysis.Downregulation of the creatine transporter SLC6A8 by JAK2.
P2860
Q26859582-ED6DC273-2BA0-4301-9C56-297E92AF0622Q28069271-D61DDE10-5384-4B28-8F7B-7AA9B8DBAF4FQ28361732-804D3AE2-129A-464A-AA7E-894135ECFBD6Q31007181-005F4575-6DCF-4A74-95D2-84CB50ED27C5Q31919248-6466D31B-A845-413E-B929-DBE97083A6EAQ33756653-05C6DB99-848D-4772-A188-378719199538Q33799314-24180D53-118D-4466-96E9-0BB3229506A3Q35602060-E8FB96FC-DBE9-415A-9F8B-90559773AC72Q35930360-EAA8E6E1-D178-4237-88F5-F9F1C38F61A5Q36251466-3818FC92-DC5A-4967-9E68-994E946C70B3Q36281111-B40463A7-E221-466C-984A-55049C72F1FCQ36646264-B5ED1DED-E9B1-4D4F-BD2A-4A0123A0C13DQ37054218-E5D64FC4-5033-4693-B54E-F60FEB819C10Q37090565-4D8B0EC4-A649-4BEE-9425-121DC08C3F8BQ37154013-64FAF5B1-767B-48D3-9A76-9D06D5B80D4AQ37434049-D45B44EA-2787-4068-A1EC-A87DD329192AQ37575876-DAF0BF30-467A-487E-9E7F-0BBC1F7443A5Q37608595-7353AB16-BF58-4CBE-9F1F-FEDEE9942B1FQ37699474-3B441322-750D-4776-948C-5438B3516621Q37853058-D9462284-51B0-4A86-A115-01E592C7D8FDQ38057699-2E035964-34A6-4062-9DEF-1920163B6F24Q38204256-FE8F7994-7031-4CB8-B5A8-E9992CA677FBQ38706110-092A99D6-137A-45DB-A360-6B5FC024B649Q39321477-B6EF33F9-C457-4A02-9647-32C712660455Q39395331-DED218B0-CA40-47D4-AE4F-60B950FAA1AEQ40372477-C1236705-FCCE-49A0-A3DC-211E04D41057Q40858046-D59AE3C1-13E8-415D-BA8A-C51DA1E16E6BQ42721547-FA4EC1DA-ED49-4F9F-8BAB-07C7C4342CB1Q43585286-ACA116BC-DB2E-482A-BE24-5201BFE5F28EQ44058344-E753C17D-7215-4A4F-AE6D-ED42DBEC1450Q44068498-5681CEEB-48DD-4C1C-8189-625FFAB29039Q44081140-46FDED57-2B30-491B-B1FB-D370B87C504CQ44213330-1A3C5112-A8C4-41E8-999D-FD73E86813ECQ44218024-C8E78C00-0648-4E84-8A5B-4892F851130CQ44280878-AD8C5054-F95B-4C22-BD7F-DF4F7EBC2A84Q44336317-21E5CDBB-E42A-431E-B2E7-E4BFA6F44552Q46834237-8FFE645F-D6BC-40BA-8734-3C11BFBABCC0Q46914976-80576191-115B-40EE-AE86-8D45286B8500Q47418424-C41964C3-2240-4A79-AF88-0F49952F238EQ48653545-C9298AF0-0896-4A89-B651-99412D628600
P2860
Downregulation of the Na(+)-creatine cotransporter in failing human myocardium and in experimental heart failure.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Downregulation of the Na
@nl
Downregulation of the Na(+)-cr ...... in experimental heart failure.
@en
type
label
Downregulation of the Na
@nl
Downregulation of the Na(+)-cr ...... in experimental heart failure.
@en
prefLabel
Downregulation of the Na
@nl
Downregulation of the Na(+)-cr ...... in experimental heart failure.
@en
P2093
P1433
P1476
Downregulation of the Na(+)-cr ...... in experimental heart failure.
@en
P2093
Hasenfuss G
Neubauer S
Spindler M
Wallimann T
Wiesmann F
P304
P356
10.1161/01.CIR.100.18.1847
P407
P577
1999-11-01T00:00:00Z